Who discovered chloroform?

Last weeks Did You Know:
Which of the following antacids were developed in 1928, in the basement laboratory of St. Louis Pharmacist Jim Howe, who invented them to help his wife’s indigestion problem?
Answer:
Tums

Richard Fan

Richard Fan is a practicing emergency/trauma physician assistant in a busy Southern California ER, and an medical officer on the federal disaster response team, DMAT CA-1. Mr. Fan teaches a free video e-course on emergency suture techniques. Learn a little, save a life at www.HowToSuture.net.
 Routinely treating victims of assault, rape, and robbery, he has developed [...]

Amneal Expands Generic Portfolio

Hauppauge, NY – Amneal Pharmaceuticals announces the availability of its Alprazolam Extended Release Tablets in strengths of 0.5 mg, 1 mg, 2 mg and 3 mg.  The company also announces the availability of its Benazepril HCl Tablets in strengths of 5 mg, 10 mg, 20 mg and 40 mg.
Alprazolam ER is an anti-anxiety Schedule-IV controlled [...]

Rx Times Magazine

Rx Times Magazine is an online journal dedicated to providing pharmacists and pharmacy technicians with information relevant to today’s pharmacy practice to assist in improving patient care.  Our ePublication offers pharmacy professionals one-stop access to information which impacts the daily operations of the pharmacy profession and business. Find information on Career Opportunities, Industry News, Current [...]

Who was Jim Howe?

Results revealed next week.

Benign Paroxysmal Positional Vertigo

 For Robert, a 54 year old sales executive, effective treatment for his Benign Paroxysmal Positional Vertigo (BPPV) was a long time in coming. His story, typical of those who suffer from BPPV, shows how frustrating this treatable, recurrent condition can be for patients and physicians, and highlights the need for improved access to the right [...]

Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease

CRANBURY, N.J., Oct. 2 — Amicus Therapeutics (Nasdaq: FOLD) today announced preliminary results from its Phase 2 randomized, open-label study to assess the safety, tolerability and preliminary efficacy of its investigational drug, Plicera(TM) (afegostat tartrate), in treatment-naive adult patients with type 1 Gaucher disease. Two dose regimens of Plicera (225 mg three days on/four days [...]

Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers

CALGARY, Oct. 2  – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and [...]

Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine

LYON, France and SWIFTWATER, Pa., Oct. 1  – Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults 18 years through 64 years of age and over the age [...]

Newly published Phase III data show Novartis drug Sandostatin® LAR Depot reduced risk of disease progression by 66% in advanced NET patients

East Hanover, N.J. (October 1, 2009) — Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) experienced a 66% reduction in risk of disease progression versus placebo1. Sandostatin LAR is indicated to treat [...]

Next Page »